Table 1 Characteristics of included studies (n = 23)
Author, year | Country | Mean age | n (male%) | Tumor location | Parameters (cut-off) | Treatment options | follow-up time (month) | Analysis variate | Outcomes | NOS |
|---|---|---|---|---|---|---|---|---|---|---|
Cho, 2015 [13] | Korea | 61.0 | 106 (70.8%) | BTC | SUVmax (7.5) | palliative chemotherapy | 7.8 | M | OS | 8 |
Furukawa, 2009 [14] | Japan | 69.0 | 69 (58.0%) | BTC | SUVmax (6.3) | surgery, palliative therapy | 53.0 | U | OS | 8 |
Harimoto, 2019 [15] | Japan | – | 24 (66.7%) | ICC | SUVmax(9.6),TLG(352.8), MTV(81.2) | surgery | – | M | OS, DFS | 7 |
Haug, 2011 [16] | Germany | – | 26 (58.0%) | ICC | △SUVmax | 90Y microspheres | – | U | OS | 6 |
Hwang, 2021 [17] | Korea | 68.5 | 55 (49.0%) | CCA | SUVmax (7.2) | chemotherapy | 33.0 | U | OS | 7 |
Kim, 2019 [18] | Korea | 72.0 | 234 (52.6%) | ECC | SUVmax (5.0), LN SUVmax (5.0) | surgery, palliative therapy | 13.5 | M | OS | 9 |
Kitamura, 2010 | Japan | 66.0 | 73 (63.0%) | ECC | SUVmax (5.7) | surgery, chemotherapy | – | M | OS | 7 |
Kobayashi, 2010 | Japan | 64.0 | 36 (na) | BTC | SUVmax (2.8) | surgery | 17.2 | M | OS | 8 |
Kubo, 2022 [11] | Japan | 68.0 | 67 (59.7%) | BTC | SUVmax (4.1), LN SUVmax (2.8) | surgery | 24.0 | M | OS, DFS | 8 |
Lee, 2013 [21] | Korea | 68.5 | 61 (52.5%) | BTC | SUVmax (5.5) | surgery, palliative therapy | – | M | OS | 7 |
Lee, 2015 [] | Korea | 67.0 | 25 (88.0%) | ECC | SUVmax (4.0), TLG (13), MTV(2.8) | surgery | 38.9 | M | OS, DFS | 8 |
Lee, 2017 [22] | Korea | 68.0 | 76 (75.0%) | ICC | SUVmax (7.3), TLG (336.6), MTV (263.6) | surgery, palliative therapy, no therapy | 5.4 | M/U | OS | 7 |
Levillain, 2019 [23] | Belgium | 58.0 | 37 (40%) | ICC | SUVmax(9),TLG(249), MTV(59) | 90Y microspheres | 6.3 | U | OS | 8 |
Pak, 2014 [24] | Korea | 73.0 | 64 (60.9%) | CCA | SUVmax(6.9) | palliative treatment | – | U | OS | 6 |
Park,2014 [25] | Korea | 61.3 | 64 (65.5%) | BTC | SUVmax (5.0) | surgery | 27.0 | M | DFS | 8 |
Sabaté-Llobera, 2018 [26] | Spain | 68.0 | 60 (60.0%) | CCA | SUVmax (6.6) | surgery, palliative therapy | 18.5 | U | OS | 6 |
Seo,2008 [27] | Japan | 64.0 | 27 (55.6%) | ICC | SUVmax (8.5) | surgery | 20.9 | M | DFS | 8 |
Seo,2019 [8] | Japan | 68.0 | 94 (58.8%) | ICC | SUVmax (8.0) | surgery | 36.0 | M | OS, DFS | 9 |
Yi, 2018 [28] | Korea | 68.0 | 40 (60.0%) | ICC | SUVmax (2.7), TLG (2.0), MTV (0.6) | surgery | 63.3 | M/U | OS | 7 |
Yho, 2019 | Japan | 69.5 | 82 (65.1%) | ICC | SUVmax (8.0) | surgery | 28.2 | M | OS, DFS | 9 |
Choi, 2017 | USA | 61.0 | 48 (70.8%) | BTC | SUVmax (8.7) | Gem±erlotinib | 40.0 | U | OS | 7 |
Jo,2017 [30] | Korea | 64.0 | 75 (57.3%) | BTC | SUVmax (9.0), â–³SUVmax | chemotherapy | 6.8 | M | OS, PFS | 9 |
Zhu, 2010 [31] | USA | 60.0 | 35 (60.0%) | BTC | △SUVmax | Bev + Gem+OXA | 12.7 | M | OS, PFS | 8 |